Gracell Biotechnologies Inc. (GRCL)

NASDAQ: GRCL · IEX Real-Time Price · USD
1.98
-0.08 (-3.88%)
Mar 24, 2023, 4:00 PM EDT - Market closed
-3.88%
Market Cap 134.05M
Revenue (ttm) 54,627
Net Income (ttm) -84.29M
Shares Out 67.70M
EPS (ttm) -1.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 401,058
Open 2.00
Previous Close 2.06
Day's Range 1.93 - 2.07
52-Week Range 1.68 - 5.69
Beta -1.85
Analysts Buy
Price Target 14.57 (+635.86%)
Earnings Date May 15, 2023

About GRCL

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 8, 2021
Employees 348
Stock Exchange NASDAQ
Ticker Symbol GRCL
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for GRCL stock is "Buy." The 12-month stock price forecast is $14.57, which is an increase of 635.86% from the latest price.

Price Target
$14.57
(635.86% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

SAN DIEGO and SUZHOU, China and SHANGHAI, China, March 22, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical c...

4 days ago - GlobeNewsWire

Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update

SAN DIEGO and SUZHOU, China and SHANGHAI, China, March 13, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or the “Company”), a global clinical-stage biopharmaceutical ...

1 week ago - GlobeNewsWire

Gracell Biotechnologies to Participate in Oppenheimer 33rd Annual Healthcare Conference

SAN DIEGO Calif., and SUZHOU and SHANGHAI, China , Feb. 28, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical com...

3 weeks ago - PRNewsWire

Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , Feb. 27, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "C om pany"), a global clinical-stage biopharmaceutical ...

3 weeks ago - PRNewsWire

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

Approval follows U.S. FDA clearance of IND application for BCMA/CD19 dual-targeting FasTCAR-T GC012F Company plans to initiate Phase 1/2 clinical trial in China in third quarter of 2023 SAN DIEGO, Cal...

1 month ago - PRNewsWire

Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma

BCMA/CD19 dual-targeting FasTCAR-T GC012F has demonstrated deep responses and favorable safety profile in proof of concept clinical studies Company plans to initiate Phase 1b/2 clinical trial in the U...

1 month ago - PRNewsWire

7 Cheap But Risky Biotech Stocks

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

2 months ago - Barrons

Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate

BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64th American Society of Hematology Annual Meeting and Exposition SAN DIEGO and SUZHOU and SHANGHAI, China , Dec...

3 months ago - PRNewsWire

Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award

FasTCAR next-day manufacturing autologous CAR-T platform recognized with prestigious biotech innovation award SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , Nov. 16, 2022 /PRNewswire/ -- Gracell B...

4 months ago - PRNewsWire

Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or “Company”), a global clinical-stage biopharmaceutical comp...

4 months ago - GlobeNewsWire

Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition

BCMA/CD19 dual-targeting FasTCAR-T GC012F demonstrated 100% ORR and 100% MRD negativity in the 13 patients treated SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , Nov. 3, 2022 /PRNewswire/ -- Gracell ...

5 months ago - PRNewsWire

Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , Oct. 31, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated t...

5 months ago - PRNewsWire

Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia

C linical trial  assessing allogeneic, HLA-matched, donor-derived allogeneic CAR-T therapy SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , Oct. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("...

5 months ago - PRNewsWire

Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , Sept.

6 months ago - PRNewsWire

Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , Aug. 29, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated t...

7 months ago - PRNewsWire

Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or “Company”), a global clinical-stage biopharmaceutical comp...

7 months ago - GlobeNewsWire

Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , Aug. 2, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to...

8 months ago - PRNewsWire

Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer

Dr. Li brings deep oncology clinical development, medical affairs and U.S. regulatory experience SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , Aug. 1, 2022 /PRNewswire/ -- Gracell Biotechnologies...

8 months ago - PRNewsWire

Gracell Biotechnologies to Participate in BTIG 2022 Biotechnology Conference

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , July 26, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated t...

8 months ago - PRNewsWire

Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , July 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical comp...

8 months ago - PRNewsWire

Gracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-targeting FasTCAR GC012F in RRMM at EHA2022 Congress, Highlighting 100% MRD Negativity Rate in All Treated Patients

Gracell also presented data on GC012F for treatment of B-NHL and allogeneic TruUCAR-candidate GC502 for treatment of B-ALL Management to host clinical update call on Monday, June 13, at 8:00AM ET SAN ...

10 months ago - PRNewsWire

Gracell Biotechnologies Schedules Clinical Update Call After EHA2022

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , June.

10 months ago - PRNewsWire

Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory Multiple Myeloma at 2022 ASCO Annual Meeting

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , May 26, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical compa...

10 months ago - PRNewsWire

Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, May 16, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or “Company”), a global clinical-stage biopharmaceutical compa...

11 months ago - GlobeNewsWire

Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , May 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company ...

11 months ago - PRNewsWire